A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-small-Cell Lung
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 520 (planned)
- Started
- Nov 11, 2022
- Main results expected
- Aug 17, 2027
- Fully finished
- Aug 18, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)
Measured over: Up to 1 year 6 months
Cohort 4: Number of Participants with Adverse Events (AEs)
Measured over: Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with AEs by Severity
Measured over: Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
Measured over: Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
Measured over: Up to approximately 4 years and 9 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05498428 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC